Publications by authors named "D S Massi"
Background: Cutaneous melanoma (CM) is rare in adolescents and young adults (AYA, 15-39 years at cancer diagnosis) and studies on CM in AYAs are scarce. Our aim is to update CM incidence and survival in European AYAs and to compare incidence and survival both with other age groups and over time.
Methods: We used the EUROCARE-6 database (108 cancer registries; 29 EU countries), calculating incidence rates (IR) per 100,000 individuals/year in the European population (years of diagnosis: 2006-2013), 5-year relative survival (RS), and 5-year RS conditional to surviving the first year after diagnosis, for the follow-up period 2010-2014 (cases diagnosed in 2006-2013).
Human leishmaniasis is facing important epidemiological changes in Southern Europe, driven by increased urbanization, climate changes, emerging of new animal reservoirs, shifts in human behavior and a growing population of immunocompromised and elderly individuals. In this evolving epidemiological landscape, we analyzed the clinical and epidemiological characteristics of human leishmaniasis in the Tuscany region of Central Italy. Through a multicentric retrospective analysis, we collected clinical and demographic data about all cases of leishmaniasis recorded between 2018 and 2023.
View Article and Find Full Text PDFArticle Synopsis
- - Chorioangiomas are benign tumors originating from chorionic tissue, found in about 1% of all examined placentas, and are mostly small and asymptomatic, often going unnoticed during ultrasounds.
- - Larger chorioangiomas (over 4-5 cm) can be detected through ultrasound and are linked to potential complications for both the mother and fetus, such as preeclampsia and fetal growth issues.
- - The study analyzes 30 cases of placental chorioangiomas, focusing on their clinical and pathological characteristics and exploring the possible molecular mechanisms behind their occurrence.
Background: Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine outcomes of CA melanoma patients receiving anti PD-1 antibodies.
Methods: Melanoma patients ≤18 years treated with anti PD-1 were retrospectively retrieved from 15 academic centers.
Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples.
Appl Immunohistochem Mol Morphol
September 2024
Article Synopsis
- Targeting the PD1/PD-L1 immune checkpoint pathway has become a key treatment strategy for melanoma patients, with PD-L1 expression testing becoming essential for access to immunotherapy.
- Current methods for evaluating PD-L1 in melanoma samples face significant challenges despite increasing demand and experience in the field.
- This technical report introduces and validates a double staining protocol for PD-L1/SOX10 that enhances the ability to clearly identify PD-L1 positive melanoma cells and encourages further research on its practical applications and consistency across different pathologists.